FDA Submission for Dapagliflozin by Jiangsu Hansoh Pharma
The submission of Dapagliflozin by Jiangsu Hansoh Pharma represents a significant competitive move in the SGLT2 inhibitor market. This could disrupt existing market dynamics and necessitate strategic adjustments from established players to maintain their market positions.
| Drug | MOA / Company | Stage |
|---|---|---|
| Dapagliflozin | Jiangsu Hansoh Pharma | Lead |
Focal Asset
Dapagliflozin
Company
Jiangsu Hansoh Pharma
Indication
Diabetes / SGLT2 Inhibitor
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The submission of Dapagliflozin by Jiangsu Hansoh Pharma represents a significant competitive move in the SGLT2 inhibitor market. This could disrupt existing market dynamics and necessitate strategic adjustments from established players to maintain their market positions.
Why it matters
The submission of Dapagliflozin by Jiangsu Hansoh Pharma represents a significant competitive move in the SGLT2 inhibitor market. This could disrupt existing market dynamics and necessitate strategic adjustments from established players to maintain their market positions.
What changed
Regulatory Approval
Analysis
Jiangsu Hansoh Pharma has submitted an original application (ANDA216119) for Dapagliflozin, currently under standard review.
The submission of Dapagliflozin by Jiangsu Hansoh Pharma represents a significant competitive move in the SGLT2 inhibitor market. This could disrupt existing market dynamics and necessitate strategic adjustments from established players to maintain their market positions.
Monitor the review progress and any subsequent approval outcomes for ANDA216119.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.